Alpha Teknova, Inc. TKNO
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +93.95%
- 1 year
- +55.16%
- Market cap
- 454.75M
- Revenue (ttm)
- 36.35M
- Profit margin
- -87.17%
- EPS (ttm)
- -0.31
- Shares out
- 53.31M
- Forward P/E
- -19.69
- YTD return
- +93.95%
- 1-year return
- +55.16%
- Volume
- 371.99K
- Avg volume
- 426.58K
- Open
- 7.44
- Previous close
- 7.34
- Day's range
- 6.88 – 7.64
- 52-week range
- 1.91 – 9.48
- Beta
- 0.36
- Analysts
- Buy
- Price target
- 8.00 (+8.5%)
- Earnings date
- Aug 13, 2024
YTD +3.47 (+88.97%)
Key statistics
- Enterprise value
- 399.47M
- PEG ratio
- 0.00
- Price / sales
- 11.26
- Price / book
- 4.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 17.20%
- Free cash flow
- -4.99M
- Total cash
- 31.69M
- Total debt
- 30.59M
- Return on equity
- -33.90%
- Short % of float
- 1.33%
- 50-day average
- 7.11
- 200-day average
- 3.96
Analyst view
Consensus: buy
- Strong buy0
- Buy3
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -0.15 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.13 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.20 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 11, 2024 | Dec 1, 2023 | -0.23 | -0.22 | +0.01 | +4.35% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 10, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| May 14, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| Mar 12, 2024 | BTIG | down | Buy | Neutral |
| Jul 12, 2023 | Keybanc | init | — | Sector Weight |
| Aug 11, 2022 | Stephens & Co. | main | — | Overweight |
| Mar 16, 2022 | Stephens & Co. | main | — | Overweight |
About Alpha Teknova, Inc.
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- teknova.com
News
Alpha Teknova Q3 Earnings Call Highlights
Alpha Teknova, Inc. (TKNO) Q3 2026 Earnings Call Transcript
Alpha Teknova (TKNO) Reports Q3 Loss, Tops Revenue Estimates
Alpha Teknova Q3 2026 Earnings Call Transcript Alpha Teknova Raises FY2026 Sales Guidance from $45.000M-$47.000M to $46.000M-$48.000M vs $46.058M Est
Alpha Teknova Q3 EPS $(0.06) Beats $(0.07) Estimate, Sales $12.704M Beat $11.639M Estimate
Teknova Reports Third Quarter 2026 Financial Results
Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
Tesla, Lam Research, Rollins And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on TKNO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEMSKI MARTHA J. | Director | Stock Award(Grant) | Jun 25, 2024 | 20,000 |
| GELHAUS KEN | Officer | Purchase | Nov 29, 2023 | 22,924 |
| GUNSTREAM STEPHEN | Chief Executive Officer | Purchase | Jul 11, 2024 | 243,497 |
| HOOD LISA | Officer | Sale | Jun 12, 2023 | 33,834 |
| LOWELL MATTHEW | Chief Financial Officer | Purchase | Jul 11, 2024 | 128,376 |
| MACKOWSKI J MATTHEW | Director | Purchase | Sep 18, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Balyasny Asset Management LLC | 1.88% | 1,000,090 | 7.68M | Sep 29, 2024 |
| Millennium Management Llc | 1.38% | 737,215 | 5.66M | Sep 29, 2024 |
| Vanguard Group Inc | 1.05% | 560,860 | 4.31M | Sep 29, 2024 |
| Roubaix Capital, LLC | 0.78% | 416,416 | 3.20M | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 0.69% | 366,400 | 2.81M | Sep 29, 2024 |
| Conestoga Capital Advisors, LLC | 0.57% | 305,129 | 2.34M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.57% | 303,047 | 2.33M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.45% | 240,629 | 1.85M | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 110,000 | 844.80K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.14% | 75,363 | 578.79K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.09% | 47,379 | 363.87K | Oct 30, 2024 |
| Conestoga Discovery Fund | 0.06% | 30,716 | 235.90K | Sep 29, 2024 |
